Within the past 3 months, there have been multiple updates to guidelines for a variety of cancers and diseases released. The treatment landscape has been evolving in malignancies such as cervical, vulvar, gastric, lung, skin, and multiple myeloma, as well as diabetes. The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have updated a few of their guidelines to reflect these changes.
B-cell malignancies are among the most deadly and difficult-to-treat blood disorders. Our understanding of treatment options, prognostic indicators, and value in B-cell malignancies is constantly evolving.